Business
GSK Shares Surge Following $2.2 Billion Zantac Settlement
Shares in pharmaceutical giant GlaxoSmithKline (GSK) surged by more than 6% after the company announced a settlement of up to $2.2 billion (€2.01 billion) to resolve tens of thousands of lawsuits in the US related to its discontinued heartburn medication, Zantac. The drug, once a blockbuster, had faced multiple allegations of causing cancer.
The settlement covers approximately 93% of the claims GSK was facing, which involves around 80,000 plaintiffs. An additional $70 million (€64 million) will be paid to resolve a whistleblower lawsuit brought by the US independent laboratory Valisure, which accused GSK of committing fraud by hiding the potential cancer risks associated with Zantac.
The whistleblower settlement is a “Qui Tam” case under the Financial Conduct Authority (FCA), a type of lawsuit where whistleblowers can file on behalf of the US government. Valisure’s claims played a significant role in the controversy surrounding the drug.
Zantac’s History and Concerns
Zantac, first introduced in the US in 1983, quickly became one of the world’s best-selling drugs, generating more than $1 billion (€0.91 billion) in annual sales. It was marketed by several major pharmaceutical companies, including Sanofi, Pfizer, and Boehringer Ingelheim.
However, concerns about the drug’s safety began to emerge in recent years. The key ingredient in Zantac, ranitidine, was found to potentially convert into a carcinogen, N-nitrosodimethylamine (NDMA), when stored at higher temperatures or over long periods. This prompted a series of recalls starting in 2019, with the US Food and Drug Administration (FDA) recalling the drug in 2020. Other countries, including the UK, Australia, and the European Union, also issued recalls.
Despite the legal settlement, GSK has continued to deny any wrongdoing, maintaining that the evidence linking ranitidine to cancer is inconsistent and unreliable.
GSK’s Statement on the Settlement
In a statement, GSK said: “While the scientific consensus remains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, GSK strongly believes that these settlements are in the best long-term interests of the company and its shareholders as they remove significant financial uncertainty, risk, and distraction associated with protracted litigation.”
The company expects to record a charge of £1.8 billion (€2.15 billion) in its third-quarter results for 2024 in connection with the settlements. Despite the financial impact, GSK assured that these costs would not affect its growth agenda or research and development investment plans.
GSK’s stock rally reflects investor confidence that the settlement will bring resolution to the long-standing litigation and remove a significant overhang for the company.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
